Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced by Rui Finance, highlighting Zhao Yan, the Chairman of Huaxi Biological, as a notable figure [1] - The selection criteria for the list included professional ability, performance, and industry influence [1] - Zhao Yan has been instrumental in the strategic transformation, R&D investment, and technological innovation of the group, solidifying its leading position in hyaluronic acid globally and expanding into cutting-edge fields like synthetic biology and regenerative medicine [2] Group 2 - Zhao Yan was born in July 1966 and holds a bachelor's degree in biology and an MBA from Fordham University [2] - She served as the General Manager of Huaxi Xinyu Investment Co., Ltd. from 2000 to 2002 and was a board member of Huaxi Furuida Biopharmaceutical Co., Ltd. from 2003 until March 2019 [2] - Currently, she holds the positions of Chairman and General Manager of the company [2]

| | | "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 俞熔，1971年12月出生，毕业于上海交通大学电子工程系，上海财经大学金融学硕士、中国中医科学院 博士、中欧国际工商管理学院EMBA。俞熔是美年健康创始人及实际控制人，现任公司董事长、上海天 亿实业控股集团有限公司董事长、中国上市公司协会副会长、中国上市公司协会医疗健康行业委员会主 任委员、国家卫生计生委健康促进与教育专家指导委员会委员、中华中医药学会健康服务工作委员会顾 问、南京医科大学校董、中国老年保健协会数智健康保障分会副主任委员、中国非公立医疗机构协会常 务理事、中国非公立医疗机构协会健康体检分会会长。 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物青事长 | | 3 | 严建亚 | 巨子生物毒事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物青事长 | | 8 | 前熔 | ...

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | T | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物董事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷节事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨貴 | 锦波生物青事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮董事长 | | | 榜单尚明:排名不分先后,围绕专业能力、业绩表现 行业11号 | | | | 响力等维度综合评选得出。 | | 2025年，在简军带领下，集团经营效率与盈利能力显著提升，加速拓展全球市场，技术储备丰富， 推"嗗科拉"等新品并拓展毛发健康、化妆品原料新赛道。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 简军，1963年11月出生，清华大学工商管理硕士。1985年至1989年于中国粮油食品进出口总公司工作； 1990年至1995年于美国B ...

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物青事长 | | 3 | 严建亚 | 巨子生物毒事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物青事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美节事长 | | 10 | (1) 郭振宇 | 贝泰妮青事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业 景 | | | | 响力等维度综合评选得出。 | | "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 傅海曙，于1999年7月毕业于上海医科大学（现称复旦大学上海医学院）临床医学专业。他是集团创办 人、执行董事及董事会主席，亦为公司提名委员会及战略投资委员会主席以及薪酬委员会成员，他负责 集团的整体管理、决策及策略规划。其在医疗美容行业拥有逾16年经验，创办集团前曾于瑞安市红十字 医 ...

Core Viewpoint - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced, highlighting key leaders in the sector, including Yan Jianya, Chairman of Juzi Biotechnology, who was recognized for his contributions and leadership [1][2]. Group 1: Industry Recognition - The list was compiled based on professional capabilities, performance, and industry influence [1]. - Yan Jianya was selected for his significant impact in the medical aesthetics field [1]. Group 2: Company Leadership - Yan Jianya, born in September 1966, holds a Bachelor's degree in Chemical Engineering from Northwest University in China [2]. - He has been the Executive Director, Chairman, and CEO of Juzi Biotechnology since November 30, 2021, and has held various leadership roles in other companies [2]. - Under his leadership, the company achieved revenue and profit growth in 2025, capitalizing on technological breakthroughs, brand upgrades, channel expansion, and policy benefits [2].

Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetic Industry for 2025" list was announced by Rui Finance, focusing on professional ability, performance, and industry influence [1][2] - Yang Xia, the Chairman of Jinbo Biological, was selected for the list, highlighting her significant contributions to the industry [1][2] - Under Yang Xia's leadership, the group achieved dual improvements in performance and brand through technological breakthroughs, product innovation, market expansion, and internationalization [2] Group 2 - Yang Xia has a Master's degree and has held various positions, including lecturer at Shanxi Medical University and executive director at Jinbo Limited [2] - Since December 2016, Yang Xia has served as the Chairman of the company and has also been the head of the research institute since December 2019 [2] - The company has become a benchmark for domestic humanized collagen in the field, reflecting its leadership in the industry [2]

Investment Rating - The industry maintains a "Recommended" rating, with a focus on service consumption, beauty care, IP derivatives, and gold jewelry as new consumption sectors [6][30]. Core Insights - The total retail sales of social consumer goods in 2025 reached 50.12 trillion yuan, a year-on-year increase of 3.69%. In December, the retail sales totaled 4.51 trillion yuan, growing by 0.9% year-on-year, which was below the consensus expectation of 1.5% [3][24]. - The report highlights significant growth in specific retail categories, with home appliance retail sales increasing by 11%, and retail sales of communication equipment, cultural and office supplies, and furniture growing by 20.9%, 17.3%, and 14.6% respectively [3][24]. - The beauty care sector is seeing innovation, with Proya launching a new PROYA MED series aimed at specific skin repair needs, and Langzi Co. forecasting a net profit of 2.2 to 2.9 billion yuan for 2025, marking a year-on-year growth of 1.09% to 33.25% [27][28]. Summary by Sections Market Performance - From January 19 to January 23, 2026, the trade retail, social services, and beauty care sectors increased by 2.16%, 3.20%, and 1.98% respectively, ranking 16th, 12th, and 17th among 31 primary industries [15][20]. Key Industry Data and News - The report notes that the retail sales of consumer goods in 2025 were driven by the replacement of old appliances, with significant growth in various categories. The retail sales of cosmetics grew by 5.1%, while gold and jewelry retail sales increased by 12.8% [24]. - Notable company activities include Bubble Mart's share repurchase of approximately 3.5 billion Hong Kong dollars and the expected profitability turnaround for Guilin Tourism, projecting a net profit of 11 million yuan in 2025 [4][28]. Investment Recommendations - The report emphasizes a focus on service consumption and highlights specific companies such as Ruoyuchen, Maogeping, Shangmei Co., Bubble Mart, Chaohongji, and Laopu Gold as key investment targets [6][30].

Investment Rating - The industry maintains a "Recommended" rating, with a focus on service consumption, beauty care, IP derivatives, and gold jewelry as new consumption sectors [6][30]. Core Insights - The total retail sales of social consumer goods in 2025 reached 50.12 trillion yuan, a year-on-year increase of 3.69%. In December, the retail sales totaled 4.51 trillion yuan, growing by 0.9% year-on-year, which was below the consensus expectation of 1.5% [3][24]. - The report highlights significant growth in specific retail categories, with home appliance retail sales increasing by 11%, and retail sales of communication equipment, cultural and office supplies, and furniture growing by 20.9%, 17.3%, and 14.6% respectively [3][24]. - The beauty care sector is seeing innovation, with Proya launching a new PROYA MED series aimed at specific skin repair needs, and Langzi Co. forecasting a net profit of 2.2 to 2.9 billion yuan for 2025, marking a year-on-year increase of 1.09% to 33.25% [27][28]. Summary by Sections Market Performance - From January 19 to January 23, 2026, the trade retail, social services, and beauty care sectors increased by 2.16%, 3.20%, and 1.98% respectively, ranking 16th, 12th, and 17th among 31 primary industries [15][18]. Key Industry Data and News - The report notes that the retail sales of consumer goods in 2025 were driven by the replacement of old appliances, with significant growth in various categories, including a 15.7% increase in sports and entertainment products [3][24]. - The beauty care sector is highlighted with new product launches and positive earnings forecasts from companies like Langzi and Meili Tianyuan, which expects a revenue of at least 30 billion yuan in 2025, growing by no less than 16% [27][28]. Investment Recommendations - The report suggests focusing on companies such as Ruoyu Chen, Mao Ge Ping, Shangmei Co., Pop Mart, Chao Hong Ji, and Lao Pu Gold as potential investment targets within the recommended sectors [6][30].

Market Overview - The medical beauty sector experienced a decline of 1.41% on January 27, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Aimei Ke (300896) closed at 140.31, down 1.20% with a trading volume of 31,300 shares and a transaction value of 439 million [1] - Jinbo Biological (920982) closed at 228.34, down 1.31% with a trading volume of 5,531 shares and a transaction value of 127 million [1] - Huaxi Biological (688363) closed at 46.43, down 1.59% with a trading volume of 49,700 shares and a transaction value of 229 million [1] - *ST Meigu (000615) closed at 3.19, down 2.15% with a trading volume of 108,900 shares and a transaction value of 34.8 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 41.32 million from main funds and a net outflow of 3.13 million from speculative funds, while retail investors had a net inflow of 44.45 million [1] - For *ST Meigu, the main funds had a net outflow of 9.71 million, accounting for -27.91% of the total, while retail investors had a net inflow of 7.40 million, representing 21.26% [2] - Huaxi Biological experienced a net outflow of 14.32 million from main funds, with a net inflow of 4.64 million from retail investors [2] - Aimei Ke had a net outflow of 17.28 million from main funds, with a net inflow of 32.41 million from retail investors [2] - Jinbo Biological saw a net outflow of 19.33 million from main funds, with a net outflow of 188,440 from retail investors [2]

Group 1 - The medical beauty sector experienced a slight decline of 0.03% on January 26, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the medical beauty sector showed mixed performance, with Huaxi Biological up 1.03% and *ST Meigu down 1.81% [1] Group 2 - The medical beauty sector saw a net outflow of 14.71 million yuan from main funds, while retail investors contributed a net inflow of 8.53 million yuan [1] - Detailed fund flow data indicates that Huaxi Biological had a main fund net inflow of 5.91 million yuan, while *ST Meigu experienced a significant main fund net outflow of 7.46 million yuan [2] - Retail investors showed a positive net inflow in several stocks, with Love Beauty seeing a retail net inflow of 26.41 million yuan despite a main fund outflow [2]